Duke University Health System Launches OneDukeGen
In a new precision medicine study, genomic and health data will be collected to understand connections between genetics, health, and disease.
The Duke University Health System and School of Medicine, in partnership with nference, an AI-enabled software platform provider, are launching OneDukeGen. The aim of this precision medicine study is to advance healthcare by integrating comprehensive genomic data and health information toward understanding hereditary disease susceptibilities.
Led by principal investigator Svati Shah, MD, MHS, Associate Dean of Genomics, the study hopes to recruit over 100,000 consented Duke patients. The study is designed to ensure a diverse representation of populations, and was informed through input from community groups. The study will also offer return of genetic sequencing results from the research.
The collaborators stated in a release that Duke researchers and clinicians who will work in tandem to integrate research findings into patient care, and hopes to bridge the gap between scientific discovery and clinical practice.
Learn more about the OneDukeGen study and how Duke patients will be invited to participate.
Reference: “Duke University Health System Launches OneDukeGen, a New Precision Medicine Study,” August 15, 2023. Duke University School of Medicine.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
